MeiraGTx Holdings plc

MGTXSEC EDGAR

Biological Products, (No Diagnostic Substances)CIK: 1735438

Concept	FY2024	FY2023	FY2021	FY2020	FY2019
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	$37.7M	$13.3M	$13.3M
Research and Development Expense	$103.8M	$85.7M	$66.7M	$24.9M	$33.6M
Operating Expenses	$151.1M	$132.3M	$110.5M	$71.6M	$78.1M
Operating Income (Loss)	-$137.1M	-$116.4M	-$72.8M	-$58.3M	-$78.1M
Interest Expense	$13.2M	$4.9M	$288.0K	$48.6K	$33.4K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$84.0M	-$129.6M	-$79.6M	-$54.7M	-$83.3M
Income Tax Expense (Benefit)	$0.00	—	$0.00	$0.00

Concept	FY2024	FY2023	FY2021	FY2020	FY2019
Assets	$326.7M	$318.2M	$320.2M	$323.9M	$96.9M
Assets, Current	$159.6M	$154.3M	$183.2M	$269.0M	$74.7M
Cash and Cash Equivalents, at Carrying Value	$129.6M	$115.5M	$137.7M	$227.2M	$68.1M
Accounts Receivable, after Allowance for Credit Loss, Current	$10.1M	$21.3M	—	—	—
Inventory, Net	$385.0K	—	—	—	—
Liabilities	$188.6M	$200.5M	$134.8M	$133.1M	$15.8M
Liabilities, Current	$67.1M	$82.1M	$68.1M	$49.2M

Concept	FY2024	FY2023	FY2021	FY2020	FY2019
Net Cash Provided by (Used in) Operating Activities	-$105.4M	-$73.1M	-$10.5M	$20.0M	-$58.9M
Net Cash Provided by (Used in) Investing Activities	$34.0M	-$45.0M	-$61.7M	-$9.4M	-$11.3M
Net Cash Provided by (Used in) Financing Activities	$84.0M	$95.2M	$1.7M	$148.2M	$130.0M
Payments to Acquire Property, Plant, and Equipment	$20.2M	$45.0M	$46.4M	$9.0M	$11.3M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)